Table of Contents
Six Australian biomedtech and health technology startups have been awarded a combined $13.5 million through the second funding round of CUREator+, marking a significant deployment of the CUREator+ $13.5 million biotech startups program aimed at fast-tracking medical breakthroughs.
What the CUREator+ $13.5 Million Biotech Startups Program Actually Provides
It is a national research translation and commercialisation program backed by the federal government with a mission to fast-track medical breakthroughs. The program, delivered by life sciences venture capital firm Brandon BioCatalyst in partnership with ANDHealth, Australia’s national commercialisation organisation for digital and connected health, is funded by the Australian Government’s Medical Research Future Fund.
Non-Dilutive Funding Structure
It offers non-dilutive capital, commercialisation support and industry network access, meaning companies receive capital without giving up an ownership stake. The program also provides milestone-based funding delivered in tranches, giving founders structured support tied to key development achievements rather than a single lump-sum disbursement.
Which Companies Received Funding From CUREator+ $13.5 Million Biotech Startups
The recipients span inflammatory disease, cancer, cardiovascular disease, neurological disorders and AI-enabled digital health, with each company receiving between roughly $1.9 million and $2.5 million to advance their technologies toward clinical and commercial milestones. The six companies, from three states, are Aleris Therapeutics and Luma Bio and WeGuide of Victoria, Frontier Inflammasome Therapeutics of Queensland, and Navier Medical and Neurotologix of Western Australia.
What Each Company Is Developing
Three of the startups, Aleris Therapeutics, Frontier Inflammasome Therapeutics and Luma Bio, will each receive A$2.5 million. Aleris Therapeutics is developing a therapy for inflammatory diseases, while Frontier Inflammasome Therapeutics is working on treatments targeting inflammatory conditions. Luma Bio is developing peptide-based radiopharmaceuticals for targeted cancer imaging and treatment. Navier Medical has been awarded A$2.13 million to develop AI-enabled cardiac CT risk markers aimed at improving the prediction and prevention of heart attacks, while WeGuide, focused on digital biomarkers, received $1.95 million.
How Navier Medical Plans to Use This CUREator+ Funding
“Preventing heart attacks starts with seeing the disease earlier,” said Sander Bangma, CEO of Navier Medical. “Our Navier Heart platform turns routine CT scans into a powerful tool for early detection and personalised treatment of cardiovascular disease, by revealing the high-risk vessels hiding in plain sight. This program supports our next critical steps,” including prospective clinical trial work, platform development, and progress toward commercial readiness.
Leadership’s Perspective on the Program’s Purpose
Dr. Amanda Vrselja, CUREator programme head, said the initiative is designed to help founders overcome the funding gap early-stage biomedtech companies commonly face. “By combining milestone-based funding with experienced commercialisation support, we’re enabling founders to build investable companies capable of delivering global healthcare impact from Australian innovation,” she said.
Government Support Behind This CUREator+ $13.5 Million Biotech Startups Round
Federal Minister for Health and Aged Care Mark Butler said the investments demonstrate the government’s commitment to turning Australian medical research into real-world treatments. “These advances have the potential to make a real difference for patients, and I look forward to seeing their impact in inflammatory disease, cancer, heart disease and beyond,” he said.
How This Round Fits CUREator’s Broader Track Record
This second CUREator+ round follows the program’s first funding round in December 2024, which deployed $18.5 million across eight startups, and a separate $15.7 million dementia-focused incubator round in September 2025. Across its various programs, CUREator-supported companies have attracted more than $150 million in external investment capital over four years, with 10,000 patients benefiting through clinical trials and implementation, according to Brandon BioCatalyst founder and CEO Dr. Chris Nave.
What This CUREator+ $13.5 Million Biotech Startups Round Means Going Forward
With this second round bringing total CUREator+ deployment across multiple funding cycles well beyond $47 million when combined with the first round and the dementia-focused incubator, the program continues building a substantial portfolio of Australian biomedtech companies spanning diverse therapeutic areas and technology types. Given CUREator’s stated track record of helping portfolio companies attract more than $150 million in follow-on external investment, this latest round of six companies may similarly serve as a springboard toward larger private capital raises as each startup hits its funded milestones.
What to Watch Going Forward
As Aleris Therapeutics, Frontier Inflammasome Therapeutics, Luma Bio, Navier Medical, Neurotologix, and WeGuide progress through their milestone-based funding tranches, industry observers will likely watch which companies successfully advance toward clinical trials or commercial readiness fastest, with Navier Medical’s cardiac CT platform already citing specific near-term clinical trial plans. Given CUREator’s pattern of running successive funding rounds across different therapeutic focus areas, this CUREator+ $13.5 million biotech startups round may be followed by additional rounds targeting other disease categories as the broader program continues deploying Medical Research Future Fund capital into Australia’s biomedtech sector.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
